FDA clears Purdue's harder-to-abuse hydrocodone Hysingla
This article was originally published in Scrip
Executive Summary
The FDA gave its blessing on 20 November for Purdue Pharma to market what is supposed to be a harder-to-abuse form of single-entity hydrocodone, which the company plans to sell under the brand name Hysingla.